open access

Vol 6, No 3 (2002)
REVIEV
Published online: 2002-07-01
Get Citation

Antihypertensive Treatment and Macrovascular Complications in Type 2 Diabetes - Results of Large Clinical Trials

Liliana Majkowska
Nadciśnienie tętnicze 2002;6(3):205-216.

open access

Vol 6, No 3 (2002)
REVIEV
Published online: 2002-07-01

Abstract

Diabetes mellitus doubles the risk of cardiovascular disease. Hypertension is present in 80% of type 2 diabetic patients and substantialy accounts for increased cardiovascular morbidity and mortality. Benefits of blood pressure reduction and influence of different antihypertensive treatment on the frequency of macrovascular diabetes complications had remained uncertain until results of large clinical trials have been published. Trials UKPDS, SHEP, Syst-Eur and HOT have shown that reduction of blood pressure in type 2 diabetes significantly reduces incidence of macrovascular complications, and effects are the greater the lower blood pressure values are achived. Clinical benefits of blood pressure lowering are more evident in hypertensive diabetics than in hypertensive subjects without diabetes but to achive proper antihypertensive effect three drugs therapy usually needed. Comparative trials UKPDS, CAPPP, ABCD, FACET and HOPE have revealed that ACE inhibitors, given to hypertensive type 2 diabetics may provide special advantage to prevent macrovascular complications in addition to blood pressure control. For that reason ACE inhibitors seem to be superior to other antihypertensive agents in this group of patients. According to LIFE trial the similar beneficial effect of blockade of angiotensin II with selective angiotensin II receptor antagonist can be assumed.

Abstract

Diabetes mellitus doubles the risk of cardiovascular disease. Hypertension is present in 80% of type 2 diabetic patients and substantialy accounts for increased cardiovascular morbidity and mortality. Benefits of blood pressure reduction and influence of different antihypertensive treatment on the frequency of macrovascular diabetes complications had remained uncertain until results of large clinical trials have been published. Trials UKPDS, SHEP, Syst-Eur and HOT have shown that reduction of blood pressure in type 2 diabetes significantly reduces incidence of macrovascular complications, and effects are the greater the lower blood pressure values are achived. Clinical benefits of blood pressure lowering are more evident in hypertensive diabetics than in hypertensive subjects without diabetes but to achive proper antihypertensive effect three drugs therapy usually needed. Comparative trials UKPDS, CAPPP, ABCD, FACET and HOPE have revealed that ACE inhibitors, given to hypertensive type 2 diabetics may provide special advantage to prevent macrovascular complications in addition to blood pressure control. For that reason ACE inhibitors seem to be superior to other antihypertensive agents in this group of patients. According to LIFE trial the similar beneficial effect of blockade of angiotensin II with selective angiotensin II receptor antagonist can be assumed.
Get Citation

Keywords

type 2 diabetes; macrovascular complications; cardiovascular disease; hypertension; prospective antihypertensive trials

About this article
Title

Antihypertensive Treatment and Macrovascular Complications in Type 2 Diabetes - Results of Large Clinical Trials

Journal

Arterial Hypertension

Issue

Vol 6, No 3 (2002)

Pages

205-216

Published online

2002-07-01

Bibliographic record

Nadciśnienie tętnicze 2002;6(3):205-216.

Keywords

type 2 diabetes
macrovascular complications
cardiovascular disease
hypertension
prospective antihypertensive trials

Authors

Liliana Majkowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl